Optimizing Outcomes in Newly Diagnosed Multiple Myeloma: Integrating Anti-CD38 Monoclonal Antibody Therapy Into Clinical Practice

Released On
January 14, 2022

Expires On
January 14, 2023

Media Type

Completion Time
30 minutes


Multiple Myeloma, Bone Cancer, Brain Cancer, Breast Cancer, Gastric Cancer, Leukemia, Lymphoma, Oncology, Skin Cancer

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by American Academy of CME and Spire Learning.

Supported by an educational grant from Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)
  • Nurses — 0.5 Contact Hours (0.5 pharmacotherapeutic contact hours)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of the multiple myeloma care team including hematologists, oncologists, oncology advanced practice providers (APPs), oncology nurses, and allied health professionals (AHPs), such as pharmacists, medical technologists, and diagnostic medical sonographers.

Program Overview

Although multiple myeloma (MM) remains incurable, recent advances in therapy have led to improved outcomes. Given the recently approved and emerging treatment options that offer the potential to improve progression-free and overall survival in newly diagnosed MM, selecting the optimal therapy for these patients can be challenging. Thus, this educational activity provides members of the care team with expert insights on recent clinical trials, including late-breaking findings from ASH 2021, to allow them to incorporate new treatment regimens appropriately and safely for the management of newly diagnosed MM.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • EXPLAIN the rationale for incorporating newer effective and well-tolerated agents into the frontline treatment of patients with MM
  • APPLY evidence-based recommendations for the integration of anti-CD38 monoclonal antibody therapy into the treatment of patients with newly diagnosed MM
  • IDENTIFY patients with newly diagnosed MM for whom treatment with an anti-CD38 monoclonal antibody-based therapeutic regimen would be appropriate
  • OUTLINE optimal management and reduce burden of treatment for patients with newly diagnosed MM undergoing treatment with anti-CD38 monoclonal antibody-based therapy


Faith E. Davies, MBBCh, MRCP, MD, FRCPath

Director, Clinical Myeloma Program
Perlmutter Cancer Center
Professor of Medicine
NYU Grossman School of Medicine
NYU Langone Health
New York, NY

Dr Faith E. Davies is Director, Clinical Myeloma Program, at the Perlmutter Cancer Center and Professor of Medicine, New York University (NYU) Grossman School of Medicine, NYU Langone Health, in New York, NY. She earned her medical degree from the University of Wales College of Medicine and completed her general medical training and hematology specialty training in the United Kingdom (UK). Prior to joining the faculty of NYU Langone, Dr Davies held positions with the University of Arkansas for Medical Sciences and the Institute of Cancer Research/Royal Marsden Hospital, in London, UK.

Her research focus for over 2 decades has been on the biology and treatment of multiple myeloma, in particular the examination of potential new drugs and new genetic technologies. Dr Davies is recognized internationally for her work looking at prognostic and predictive biomarkers (eg, genetic abnormalities, imaging and minimal residual disease) within the context of clinical trials. Her laboratory work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small molecule interventions and translating those laboratory findings into the clinical arena with a focus on individualized treatment.

Dr Davies is a member of the American Society of Hematology, the American Association for Cancer Research, the Royal College of Physicians (UK), and the Royal College of Pathologists (UK). She is widely published in leading peer-reviewed journals, including the New England Journal of Medicine, Lancet Oncology, Blood, Journal of Clinical Oncology, and Leukemia.

Nina Shah, MD

Professor of Clinical Medicine
Multiple Myeloma Translational Initiative
Division of Hematology-Oncology
University of California, San Francisco
San Francisco, CA

Dr Nina Shah is a Professor of Clinical Medicine in the Division of Hematology-Oncology at the University of California, San Francisco. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. Dr Shah performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is one of the lead principal investigators (PIs) for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy and immunotherapy protocols.

Dr Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She has published on the link between patient-reported outcomes and physical testing in this clinical context and is conducting a study to investigate digital life coaching during transplant recovery. Dr Shah is heavily involved in the myeloma research community and led the effort to define myeloma-transplant practice guidelines for the American Society for Blood and Marrow Transplantation (ASBMT). She also serves as a Co-Chair for the Plasma Cell Disorders and Adult Solid Tumors Working Committee at the Center for International Blood & Marrow Transplant Research (CIBMTR) and is a member of the American Society of Hematology Scientific Committee on Plasma Cell Neoplasia.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Spire Learning. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

American Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses Credit Designation

American Academy of CME, Inc., designates this educational activity for 0.5 ANCC contact hours (0.5 pharmacotherapeutic contact hours).

Disclosures of Conflicts of Interest

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of relevant financial relationships are as follows:


Faith E. Davies, MBBCh, MRCP, MD, FRCPath
  • Advisory Board/Consultant: Celgene/BMS; GlaxoSmithKline; Janssen; Oncopeptides; Sanofi; Takeda
Nina Shah, MD
  • Advisory Board/Consultant: Amgen Inc; CareDx, Inc; CSL Behring; GlaxoSmithKline; Indapta Therapeutics; Karyopharm Therapeutics Inc; Kite Pharma; Oncopeptides; Sanofi
  • Grant/Research Support (paid to her institution): Bluebird Bio; Celgene/BMS; Nektar Therapeutics; Poseida Therapeutics; Precision BioSciences, Inc; Sutro Biopharma, Inc; TeneoBio

Independent Clinical Reviewer
Laura J. Zitella, MS, RN, ACNP-BC, AOCN: No relevant financial relationships with ineligible companies.

Planning Committee
John JD Juchniewicz, MCIS, CHCP, FACEHP, Natalie Kirkwood, RN, BSN, JD, American Academy of CME: No relevant financial relationships with ineligible companies.

Spire Learning:
Mairead Early, Allison Goldberg, MPA, Chris Washburn, PhD: No relevant financial relationships with ineligible companies.

Instructions for Participation and Credit

There are no fees to participate in the activity. To receive CME/CE credit participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity, complete the post-test (achieving a passing grade of 70% or greater), and program evaluation.

Certificates will be emailed to the participant.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This activity will review investigational information regarding the use of isatuximab or ixazomib for patients with newly diagnosed multiple myeloma.


The opinions expressed in this educational activity are those of the faculty and do not represent those of the Academy or Spire Learning. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, consult appropriate resources for any product or device mentioned in this activity, and draw conclusions only after careful consideration of all available scientific information.

Contact Information

For any questions, please contact: CEServices@academycme.org

Privacy Policy

American Academy of CME Privacy Policy:
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm

Spire Learning Privacy Policy:
Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.

Collection and Use of Your Personal Information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected, retained, and used by Spire Learning, LLC to continuously improve the learning experience.

Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.


© 2022. This accredited continuing education activity is held as copyrighted © by American Academy of CME and Spire Learning, LLC. Through this notice, the Academy and Spire Learning, LLC grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).